
What Signs or Symptoms Should Be Prioritized in the Treatment of MLC? |
Information Letter
Dear parents/caregivers,
We have recently started a study on patients with MLC, a rare genetic neurological disorder characterized by motor difficulties, developmental delay, and epilepsy.
One of the aims of our study is to establish an international registry to collect clinical data about patients with MLC in a centralized and anonymous manner. With this, we hope to gain a better understanding of the disease, enabling us to provide better information to parents and patients and hopefully assess therapies effectively in the future. Please note that this message is not about the registry yet. Once the registry opens, we will inform you, so you can register your affected patient.
This message is about priorities in therapy development. We would like to know which difficulties caused by MLC you would like to see changed first or most, if treatment would be available.
In the following questionnaire, we have included four questions that focus on which improvements you consider important regarding your child with MLC.
Your input is critical. Could you kindly complete the questionnaire by May 31, 2025?
Please press ''Next'' to start the questionnaire.
Please press ''Next'' to start the questionnaire.
Kind regards,
Nicole Versaevel,
PhD Candidate
Department of Pediatric Neurology & Amsterdam Leukodystrophy Center, Emma Children’s Hospital, Amsterdam UMC
Marjo van der Knaap,
Pediatric Neurologist
Department of Pediatric Neurology & Amsterdam Leukodystrophy Center, Emma Children’s Hospital, Amsterdam UMC
Jigyasha Sinha, Pinar Topaloglu, Francesco Nicita, Paulo Sgobbi de Souza, Geneviève Bernard, Ali Fatemi, Marjo van der Knaap
The MLC Clinical Expert Consortium
Alexandra Chapleau,
PhD Candidate & Secretary Alliance MLC
Department of Neurology & Neurosurgery, McGill University, Montreal
Christina Marouda
Founder and President, Alliance MLC